prikaz prve stranice dokumenta Pharmacoeconomic aspect of moderate and severe psoriasis treatment with biological therapy versus conventional therapy
  Download
PDF 1.19 MB
doctoral thesis
Pharmacoeconomic aspect of moderate and severe psoriasis treatment with biological therapy versus conventional therapy
Zagreb: University of Zagreb, School of Medicine, 2024. urn:nbn:hr:105:766317
Orbanić, Ante
University of Zagreb
School of Medicine
Department of Dermatology

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Orbanić, A. (2024). Pharmacoeconomic aspect of moderate and severe psoriasis treatment with biological therapy versus conventional therapy (Doctoral thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:766317

Orbanić, Ante. "Pharmacoeconomic aspect of moderate and severe psoriasis treatment with biological therapy versus conventional therapy." Doctoral thesis, University of Zagreb, School of Medicine, 2024. https://urn.nsk.hr/urn:nbn:hr:105:766317

Orbanić, Ante. "Pharmacoeconomic aspect of moderate and severe psoriasis treatment with biological therapy versus conventional therapy." Doctoral thesis, University of Zagreb, School of Medicine, 2024. https://urn.nsk.hr/urn:nbn:hr:105:766317

Orbanić, A. (2024). 'Pharmacoeconomic aspect of moderate and severe psoriasis treatment with biological therapy versus conventional therapy', Doctoral thesis, University of Zagreb, School of Medicine, accessed 23 December 2024, https://urn.nsk.hr/urn:nbn:hr:105:766317

Orbanić A. Pharmacoeconomic aspect of moderate and severe psoriasis treatment with biological therapy versus conventional therapy [Doctoral thesis]. Zagreb: University of Zagreb, School of Medicine; 2024 [cited 2024 December 23] Available at: https://urn.nsk.hr/urn:nbn:hr:105:766317

A. Orbanić, "Pharmacoeconomic aspect of moderate and severe psoriasis treatment with biological therapy versus conventional therapy", Doctoral thesis, University of Zagreb, School of Medicine, Zagreb, 2024. Available at: https://urn.nsk.hr/urn:nbn:hr:105:766317

Metadata
TitlePharmacoeconomic aspect of moderate and severe psoriasis treatment with biological therapy versus conventional therapy
Title (english)Pharmacoeconomic aspect of moderate and severe psoriasis treatment with biological therapy versus conventional therapy
AuthorAnte Orbanić
MentorMirna Šitum (mentor)
MentorStjepan Orešković (komentor)
Committee memberBranka Marinović (predsjednik povjerenstva)
Committee memberMirjana Kujundžić Tiljak (član povjerenstva)
Committee memberJelena Filipović-Grčić (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
(Department of Dermatology)
Zagreb
Defense date and country2024-09-02, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Dermatovenerology
Universal decimal classification
(UDC)		616 - Pathology. Clinical medicine
Abstract
Psoriasis is a chronic, recurrent, autoimmune skin disease. In Croatia, around 80,000 people have some form of psoriasis, and 20% have moderate or severe psoriasis. The total costs of psoriasis for patients worldwide are $11.25 billion annually. This study aimed to show that using ustekinumab shows non-inferiority compared to acitretin and to evaluate the direct cost of treatment of moderate and severe psoriasis with different treatments. A Retrospective study included data from 25 patients using ustekinumab and 43 patients using acitretin. Data was collected by analyzing patients' medical records. Overall results for HRQoL and QALY were more favourable for ustekinumab 45 mg, with an HRQoL score of 0.9. The highest calculated QALY for ustekinumab 45 mg was 24.3, costing €1942.15 per QALY. Ustekinumab 45 mg showed more favourable results in terms of ICER of €-1124.25, €3721.7, and €2953.6 for PASI scores at baseline, after 12 weeks, and after 52 weeks of treatment, respectively. This research provides insight into the complex pharmacoeconomic aspects of treating moderate and severe psoriasis, highlighting the importance of a comprehensive approach to evaluating the costs and benefits of different therapeutic approaches.
Abstract (croatian)
Psorijaza je kronična, rekurentna, autoimuna bolest kože. Procjenjuje se da u Hrvatskoj oko 80 000 ljudi ima neki oblik psorijaze, a 20% pacijenata ima srednje tešku ili tešku psorijazu. Ukupni troškovi zdravstvene zaštite oboljelih od psorijaze u svijetu procjenjuju se na 11,25 milijardi dolara godišnje. Ciljevi ove studije bili su pokazati da primjena ustekinumaba nije inferiorna u usporedbi s acitretinom te procijeniti izravne troškove liječenja srednje teške i teške psorijaze ustekinumabom u usporedbi s acitretinom. Provedena je retrospektivna studija koja uključuje podatke 25 pacijenata koji su primjenjivali ustekinumab i 43 pacijenata koji su primjenjivali acitretin. Podaci su prikupljeni analizom medicinske dokumentacije pacijenata. Ukupni rezultati za HRQoL i QALY bili su povoljniji za ustekinumab 45 mg, s rezultatom HRQoL od 0,9. Najviši izračunati QALY za ustekinumab 45 mg bio je 24,3, s cijenom od 1942,15 € po QALY-u. Ustekinumab 45 mg pokazao se povoljnijim u smislu ICER-a od -1124,25 €, 3721,7 € i 2953,6 € za PASI na početku, nakon 12 tjedana odnosno nakon 52 tjedna liječenja. Ovo istraživanje pruža uvid u složene farmakoekonomske aspekte liječenja srednje teške i teške psorijaze, ističući važnost cjelovitog pristupa procjeni troškova i uporabi različitih terapijskih pristupa.
Keywords
Keywords (croatian)
Languageenglish
URN:NBNurn:nbn:hr:105:766317
Study programmeTitle: Biomedicine and Health Sciences
Study programme type: university
Study level: postgraduate
Academic / professional title: doktor/doktorica znanosti, područje biomedicine i zdravstvo (doktor/doktorica znanosti, područje biomedicine i zdravstvo)
Type of resourceText
Extent75 str.
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-10-01 08:11:24